Voyager Therapeutics (VYGR) Accounts Payables (2014 - 2026)
Voyager Therapeutics (VYGR) posted Accounts Payables of $2.7 million for Q1 2026, down 45.68% sequentially from $5.0 million in Q4 2025, and up 3.38% YoY from $2.6 million in Q1 2025.
Voyager Therapeutics (VYGR) Accounts Payables (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Accounts Payables for 13 years, with the latest figure at $2.7 million in Q1 2026.
- Quarterly Accounts Payables rose 3.38% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 3.38% YoY) and the FY2025 annual result came in at $5.0 million, up 25.45% from the prior year.
- Accounts Payables retreated to $2.7 million in Q1 2026 per VYGR's latest filing, from $5.0 million in the prior quarter.
- Over five years, Accounts Payables peaked at $7.6 million in Q1 2024 and troughed at $1.2 million in Q1 2022.
- A 5-year average of $2.8 million and a median of $2.6 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 347.04% in 2022, then slumped 65.25% in 2025.
- Over 5 years, Accounts Payables stood at $2.6 million in 2022, then sank by 37.49% to $1.6 million in 2023, then soared by 149.13% to $4.0 million in 2024, then gained by 25.45% to $5.0 million in 2025, then sank by 45.68% to $2.7 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $2.7 million, $5.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 35.57 Mn |
| 10 | Voyager Therapeutics | 204.95 Mn | 88.62 Mn | - | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 2.72 Mn |
| Dec 31, 2025 | 5.01 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 2.63 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 3.16 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 7.58 Mn |
| Dec 31, 2023 | 1.60 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 1.66 Mn |
| Mar 31, 2023 | 3.70 Mn |
| Dec 31, 2022 | 2.57 Mn |
| Sep 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 1.22 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 574,000.00 |
| Sep 30, 2021 | 592,000.00 |